Salivary metabolites are promising noninvasive biomarkers of drug-induced liver injury.

Background: Drug-induced liver injury (DILI) is one of the most common adverse events of medication use, and its incidence is increasing. However, early detection of DILI is a crucial challenge due to a lack of biomarkers and noninvasive tests.

Aim: To identify salivary metabolic biomarkers of DILI for the future development of noninvasive diagnostic tools.